• Markets
    • icon
  • Companies
NEU · ASX

Neuren Pharmaceuticals Limited (ASX:NEU)

AU$15.66

 0.0 (0.0%)
ASX:Live
05/12/2023 04:10:44 PM
Short Sold <-1 over the month HALO Small HALO Price Momentum HALO Ords HALO GARP +7
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

NEU Overview

NEU Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About NEU

Website

Neuren Pharmaceuticals Limited

Telephone

61.3.9092.0480

Address

Suite 201 697 Burke Road Camberwell, Victoria (VIC) 3124

Description

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its products include Pipeline, Trofinetide, and NNZ-2591. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.

NEU Price Chart

Key Stats

Market Cap

AU$2.08B

PE

EV/EBITDA

334.9

Dividends Overview

DIV Yield

.0%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 6.72 - 16.4

Trade Value (12mth)

AU$1,742,738.00

1 week

4.12%

1 month

27.84%

YTD

80.21%

1 year

115.11%

All time high

16.4

Key Fundamentals

EPS 3 yr Growth

-101.400%

EBITDA Margin

-10.90%

Operating Cashflow

$4m

Free Cash Flow Return

8.90%

ROIC

0.50%

Interest Coverage

N/A

Quick Ratio

25.80

Other Data

Shares on Issue (Fully Dilluted)

130m

HALO Sector

Healthcare

Next Company Report Date

28-Feb-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.23

NEU Announcements

Latest Announcements

Date Announcements

31 May 11

Neuren CEO Presentation to AGM

×

Neuren CEO Presentation to AGM

31 May 11

Results of Annual Meeting

×

Results of Annual Meeting

31 March 11

Annual Report to shareholders

×

Annual Report to shareholders

31 March 09

Annual Report to shareholders

×

Annual Report to shareholders

31 March 08

Annual Report to shareholders

×

Annual Report to shareholders

31 March 06

Annual Report

×

Annual Report

31 March 06

Notice of Annual General Meeting

×

Notice of Annual General Meeting

31 July 23

Q2 2023 quarterly activity and cash flow report

×

Q2 2023 quarterly activity and cash flow report

31 January 23

Q4 2022 quarterly activity and cash flow report

×

Q4 2022 quarterly activity and cash flow report

31 January 22

Q4 2021 quarterly activity and cash flow report

×

Q4 2021 quarterly activity and cash flow report

30 May 23

AGM Chair Address & CEO Presentation

×

AGM Chair Address & CEO Presentation

30 May 23

Results of Meeting

×

Results of Meeting

30 May 22

AGM Chairman's Address & CEO Presentation

×

AGM Chairman's Address & CEO Presentation

30 May 22

Results of Meeting

×

Results of Meeting

30 March 12

Neuren 2011 Annual Report

×

Neuren 2011 Annual Report

30 March 10

Annual Report to shareholders

×

Annual Report to shareholders

30 June 23

Neuren completes enrolment in Phelan-McDermid Phase 2 trial

×

Neuren completes enrolment in Phelan-McDermid Phase 2 trial

30 July 13

Investor presentation July 2013

×

Investor presentation July 2013

29 May 17

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

29 May 08

CEO presentation to AGM

×

CEO presentation to AGM

29 May 06

Further US Army results presented on NNZ-2566

×

Further US Army results presented on NNZ-2566

29 March 07

Annual Report

×

Annual Report

29 June 20

AGM Chairman's Address and CEO Presentation

×

AGM Chairman's Address and CEO Presentation

29 July 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 April 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 April 20

Annual Report 2019

×

Annual Report 2019

29 April 19

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

NEU Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.09 -0.07 0.00 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.09 -0.07 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 20.5 22.9 102.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A 1,826.7 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A 334.9 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.07 -0.06 0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.08 -0.08 0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock 34.1 16.9 142.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.9 -2.2 0.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.21 0.30 0.33 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.21 0.30 0.33 Lock Lock Lock
     Growth % Lock Lock Lock Lock 52.6 47.9 8.5 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 107 118 129 Lock Lock Lock
Basic m Lock Lock Lock Lock 107 118 126 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Income Statement
Sales $m Lock Lock Lock Lock 0 0 15 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 10 11 16 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 15 Lock Lock Lock
     Growth % Lock Lock Lock Lock -50.0 -33.3 181,887.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A 99.9 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -10 -11 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 17.7 -20.0 86.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -10.9 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -10 -11 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 17.7 -20.0 86.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -11.0 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -10 -11 -1 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -3 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -9 -8 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 15.0 15.2 102.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A 1.3 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -8 -10 4 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 19 22 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -8 -10 4 Lock Lock Lock
     Growth % Lock Lock Lock Lock 31.1 -23.5 135.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A 0.2 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 24 37 40 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 25 40 43 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -24 -37 -40 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 24 39 42 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 24 39 42 Lock Lock Lock
     Growth % Lock Lock Lock Lock 74.8 62.2 6.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -36.8 -19.5 0.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -38.0 -19.9 0.4 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -50.1 -36.0 -3.9 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -48.3 -24.6 0.5 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -42.5 -31.4 8.9 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.5 3.2 25.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -100.0 -93.7 -96.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 33.1 49.9 25.8 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 33.1 49.9 25.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 97.0 91.9 92.9 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -1,072.8 -1,241.6 214.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 11.6 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.4 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 1.8 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.3 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.3 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A -4.7 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A -1.6 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -36.8 -19.5 0.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.0 1.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -38.0 -19.9 0.4 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -38.0 -19.9 0.4 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 31.5 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 31.5 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 15,400.8 9,407.2 9,170.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -15,400.8 -9,407.2 -9,139.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.0%

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.23%

Value ($M)

4

Prior Change

N/A

7 Day Change

-0.30%

1 Month Change

-1.40%

3 Month Change

-0.40%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

NEU Shortsell

Frequently Asked Questions

The current share price of Neuren Pharmaceuticals Limited (NEU:ASX) is AU$15.66.
The 52-week high share price for Neuren Pharmaceuticals Limited (NEU:ASX) is AU$16.40.
The 52-week low share price for Neuren Pharmaceuticals Limited (NEU:ASX)? is AU$6.72.
The current TTM dividend payout for Neuren Pharmaceuticals Limited (NEU:ASX) is 0.00.
Neuren Pharmaceuticals Limited (NEU:ASX) does not pay a dividend.
Neuren Pharmaceuticals Limited (NEU:ASX) has a franking level of 0%.
Neuren Pharmaceuticals Limited (NEU:ASX) is classified in the Healthcare.
The current P/E ratio for Neuren Pharmaceuticals Limited (NEU:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.